Latest Precigen News & Updates

See the latest news and media coverage for Precigen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Precigen

Gene and cell therapy biopharmaceutical company

precigen.com

Headquarters: Germantown, United States
Founded year: 2020
Company type: Public company
Number of employees: 150–200

Last updated Today

Latest news about Precigen

In short: Precigen achieved a historic milestone with the FDA approval and successful commercial launch of PAPZIMEOS for recurrent respiratory papillomatosis.

Company announcements

May 30 Precigen

Precigen presents new long-term durability data for PAPZIMEOS

83% of complete responders maintained response for at least 36 months, with five beyond four years, and the drug received seven-year market exclusivity.

May 27 Precigen

Precigen will present pivotal trial data at symposium

The data shows complete responses and reduced surgical debulking in recurrent respiratory papillomatosis patients.

May 27 Precigen

Precigen receives orphan drug exclusivity for PAPZIMEOS

The FDA granted seven-year market exclusivity for the RRP treatment, effective through August 2032.

May 13 Precigen

Precigen reports Q1 2026 financial results and updates

PAPZIMEOS generated $21.6M in net product revenue, with 400 patients enrolled and strong payer coverage.

Media coverage

Yesterday Yahoo Finance

Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason

Precigen Inc. (NASDAQ:PGEN) is one of the 10 Stocks Paying Off Big Time. Precigen rallied for a second day on Monday, surging 11.62 percent to...

June 15 Yahoo Finance

Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS

Precigen Inc. (NASDAQ:PGEN) is one of the penny stocks with explosive growth potential. On June 15, Precigen secured FDA orphan drug exclusivity for PAPZIMEOS, a...

May 31 Yahoo Finance

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated...

May 27 Morningstar

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene...

Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced ...

Never miss news about Precigen

Track Precigen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Precigen competitors & trending companies

Browse news for competitors to Precigen and other trending companies.